BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 20660184)

  • 1. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection.
    Leslie A; Matthews PC; Listgarten J; Carlson JM; Kadie C; Ndung'u T; Brander C; Coovadia H; Walker BD; Heckerman D; Goulder PJ
    J Virol; 2010 Oct; 84(19):9879-88. PubMed ID: 20660184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA Class I-Mediated HIV-1 Control in Vietnamese Infected with HIV-1 Subtype A/E.
    Chikata T; Tran GV; Murakoshi H; Akahoshi T; Qi Y; Naranbhai V; Kuse N; Tamura Y; Koyanagi M; Sakai S; Nguyen DH; Nguyen DT; Nguyen HT; Nguyen TV; Oka S; Martin MP; Carrington M; Sakai K; Nguyen KV; Takiguchi M
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of HLA selection pressure on HIV fitness at a population level in Mexico and Barbados.
    Juarez-Molina CI; Payne R; Soto-Nava M; Avila-Rios S; Valenzuela-Ponce H; Adland E; Leitman E; Brener J; Muenchhoff M; Branch S; Landis C; Reyes-Teran G; Goulder P
    J Virol; 2014 Sep; 88(18):10392-8. PubMed ID: 25008926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.
    Ojwach DBA; MacMillan D; Reddy T; Novitsky V; Brumme ZL; Brockman MA; Ndung'u T; Mann JK
    J Virol; 2018 Oct; 92(19):. PubMed ID: 29997209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1.
    Tang J; Tang S; Lobashevsky E; Myracle AD; Fideli U; Aldrovandi G; Allen S; Musonda R; Kaslow RA;
    J Virol; 2002 Aug; 76(16):8276-84. PubMed ID: 12134033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.
    Sakai K; Chikata T; Brumme ZL; Brumme CJ; Gatanaga H; Oka S; Takiguchi M
    Retrovirology; 2015 Nov; 12():98. PubMed ID: 26585907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of HLA Allele-KIR Pairs on HIV Clinical Outcome in South Africa.
    Mori M; Leitman E; Walker B; Ndung'u T; Carrington M; Goulder P
    J Infect Dis; 2019 Apr; 219(9):1456-1463. PubMed ID: 30520960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles.
    Catano G; Kulkarni H; He W; Marconi VC; Agan BK; Landrum M; Anderson S; Delmar J; Telles V; Song L; Castiblanco J; Clark RA; Dolan MJ; Ahuja SK
    PLoS One; 2008; 3(11):e3636. PubMed ID: 18982067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-B*57 Micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection pressure, and HIV immune control.
    Kloverpris HN; Stryhn A; Harndahl M; van der Stok M; Payne RP; Matthews PC; Chen F; Riddell L; Walker BD; Ndung'u T; Buus S; Goulder P
    J Virol; 2012 Jan; 86(2):919-29. PubMed ID: 22090105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection.
    Brockman MA; Brumme ZL; Brumme CJ; Miura T; Sela J; Rosato PC; Kadie CM; Carlson JM; Markle TJ; Streeck H; Kelleher AD; Markowitz M; Jessen H; Rosenberg E; Altfeld M; Harrigan PR; Heckerman D; Walker BD; Allen TM
    J Virol; 2010 Nov; 84(22):11937-49. PubMed ID: 20810731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA Class I Alleles Associated with Mortality in Thai Military Recruits with HIV-1 CRF01_AE Infection.
    Gandhi RT; Bosch RJ; Rangsin R; Chuenchitra T; Sirisopana N; Kim JH; Robb ML; Vejbaesya S; Paris RM; Nelson KE
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):44-9. PubMed ID: 26383907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective Effect of HLA-B*5701 and HLA-C -35 Genetic Variants in HIV-Positive Caucasians from Northern Poland.
    Leszczyszyn-Pynka M; Aksak-Wąs B; Urbańska A; Parczewski M
    PLoS One; 2015; 10(6):e0127867. PubMed ID: 26068923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host genetics and viral load in primary HIV-1 infection: clear evidence for gene by sex interactions.
    Li X; Price MA; He D; Kamali A; Karita E; Lakhi S; Sanders EJ; Anzala O; Amornkul PN; Allen S; Hunter E; Kaslow RA; Gilmour J; Tang J;
    Hum Genet; 2014 Sep; 133(9):1187-97. PubMed ID: 24969460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human leukocyte antigen class I and class II allele frequencies and HIV-1 infection associations in a Chinese cohort.
    Li S; Jiao H; Yu X; Strong AJ; Shao Y; Sun Y; Altfeld M; Lu Y
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):121-31. PubMed ID: 17106278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.
    Kiepiela P; Leslie AJ; Honeyborne I; Ramduth D; Thobakgale C; Chetty S; Rathnavalu P; Moore C; Pfafferott KJ; Hilton L; Zimbwa P; Moore S; Allen T; Brander C; Addo MM; Altfeld M; James I; Mallal S; Bunce M; Barber LD; Szinger J; Day C; Klenerman P; Mullins J; Korber B; Coovadia HM; Walker BD; Goulder PJ
    Nature; 2004 Dec; 432(7018):769-75. PubMed ID: 15592417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.
    Carrington M; Nelson GW; Martin MP; Kissner T; Vlahov D; Goedert JJ; Kaslow R; Buchbinder S; Hoots K; O'Brien SJ
    Science; 1999 Mar; 283(5408):1748-52. PubMed ID: 10073943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MHC-driven HIV-1 control on the long run is not systematically determined at early times post-HIV-1 infection.
    Antoni G; Guergnon J; Meaudre C; Samri A; Boufassa F; Goujard C; Lambotte O; Autran B; Rouzioux C; Costagliola D; Meyer L; Theodorou I
    AIDS; 2013 Jul; 27(11):1707-16. PubMed ID: 23462218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
    ; Pereyra F; Jia X; McLaren PJ; Telenti A; de Bakker PI; Walker BD; Ripke S; Brumme CJ; Pulit SL; Carrington M; Kadie CM; Carlson JM; Heckerman D; Graham RR; Plenge RM; Deeks SG; Gianniny L; Crawford G; Sullivan J; Gonzalez E; Davies L; Camargo A; Moore JM; Beattie N; Gupta S; Crenshaw A; Burtt NP; Guiducci C; Gupta N; Gao X; Qi Y; Yuki Y; Piechocka-Trocha A; Cutrell E; Rosenberg R; Moss KL; Lemay P; O'Leary J; Schaefer T; Verma P; Toth I; Block B; Baker B; Rothchild A; Lian J; Proudfoot J; Alvino DM; Vine S; Addo MM; Allen TM; Altfeld M; Henn MR; Le Gall S; Streeck H; Haas DW; Kuritzkes DR; Robbins GK; Shafer RW; Gulick RM; Shikuma CM; Haubrich R; Riddler S; Sax PE; Daar ES; Ribaudo HJ; Agan B; Agarwal S; Ahern RL; Allen BL; Altidor S; Altschuler EL; Ambardar S; Anastos K; Anderson B; Anderson V; Andrady U; Antoniskis D; Bangsberg D; Barbaro D; Barrie W; Bartczak J; Barton S; Basden P; Basgoz N; Bazner S; Bellos NC; Benson AM; Berger J; Bernard NF; Bernard AM; Birch C; Bodner SJ; Bolan RK; Boudreaux ET; Bradley M; Braun JF; Brndjar JE; Brown SJ; Brown K; Brown ST; Burack J; Bush LM; Cafaro V; Campbell O; Campbell J; Carlson RH; Carmichael JK; Casey KK; Cavacuiti C; Celestin G; Chambers ST; Chez N; Chirch LM; Cimoch PJ; Cohen D; Cohn LE; Conway B; Cooper DA; Cornelson B; Cox DT; Cristofano MV; Cuchural G; Czartoski JL; Dahman JM; Daly JS; Davis BT; Davis K; Davod SM; DeJesus E; Dietz CA; Dunham E; Dunn ME; Ellerin TB; Eron JJ; Fangman JJ; Farel CE; Ferlazzo H; Fidler S; Fleenor-Ford A; Frankel R; Freedberg KA; French NK; Fuchs JD; Fuller JD; Gaberman J; Gallant JE; Gandhi RT; Garcia E; Garmon D; Gathe JC; Gaultier CR; Gebre W; Gilman FD; Gilson I; Goepfert PA; Gottlieb MS; Goulston C; Groger RK; Gurley TD; Haber S; Hardwicke R; Hardy WD; Harrigan PR; Hawkins TN; Heath S; Hecht FM; Henry WK; Hladek M; Hoffman RP; Horton JM; Hsu RK; Huhn GD; Hunt P; Hupert MJ; Illeman ML; Jaeger H; Jellinger RM; John M; Johnson JA; Johnson KL; Johnson H; Johnson K; Joly J; Jordan WC; Kauffman CA; Khanlou H; Killian RK; Kim AY; Kim DD; Kinder CA; Kirchner JT; Kogelman L; Kojic EM; Korthuis PT; Kurisu W; Kwon DS; LaMar M; Lampiris H; Lanzafame M; Lederman MM; Lee DM; Lee JM; Lee MJ; Lee ET; Lemoine J; Levy JA; Llibre JM; Liguori MA; Little SJ; Liu AY; Lopez AJ; Loutfy MR; Loy D; Mohammed DY; Man A; Mansour MK; Marconi VC; Markowitz M; Marques R; Martin JN; Martin HL; Mayer KH; McElrath MJ; McGhee TA; McGovern BH; McGowan K; McIntyre D; Mcleod GX; Menezes P; Mesa G; Metroka CE; Meyer-Olson D; Miller AO; Montgomery K; Mounzer KC; Nagami EH; Nagin I; Nahass RG; Nelson MO; Nielsen C; Norene DL; O'Connor DH; Ojikutu BO; Okulicz J; Oladehin OO; Oldfield EC; Olender SA; Ostrowski M; Owen WF; Pae E; Parsonnet J; Pavlatos AM; Perlmutter AM; Pierce MN; Pincus JM; Pisani L; Price LJ; Proia L; Prokesch RC; Pujet HC; Ramgopal M; Rathod A; Rausch M; Ravishankar J; Rhame FS; Richards CS; Richman DD; Rodes B; Rodriguez M; Rose RC; Rosenberg ES; Rosenthal D; Ross PE; Rubin DS; Rumbaugh E; Saenz L; Salvaggio MR; Sanchez WC; Sanjana VM; Santiago S; Schmidt W; Schuitemaker H; Sestak PM; Shalit P; Shay W; Shirvani VN; Silebi VI; Sizemore JM; Skolnik PR; Sokol-Anderson M; Sosman JM; Stabile P; Stapleton JT; Starrett S; Stein F; Stellbrink HJ; Sterman FL; Stone VE; Stone DR; Tambussi G; Taplitz RA; Tedaldi EM; Telenti A; Theisen W; Torres R; Tosiello L; Tremblay C; Tribble MA; Trinh PD; Tsao A; Ueda P; Vaccaro A; Valadas E; Vanig TJ; Vecino I; Vega VM; Veikley W; Wade BH; Walworth C; Wanidworanun C; Ward DJ; Warner DA; Weber RD; Webster D; Weis S; Wheeler DA; White DJ; Wilkins E; Winston A; Wlodaver CG; van't Wout A; Wright DP; Yang OO; Yurdin DL; Zabukovic BW; Zachary KC; Zeeman B; Zhao M
    Science; 2010 Dec; 330(6010):1551-7. PubMed ID: 21051598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disentangling human tolerance and resistance against HIV.
    Regoes RR; McLaren PJ; Battegay M; Bernasconi E; Calmy A; Günthard HF; Hoffmann M; Rauch A; Telenti A; Fellay J;
    PLoS Biol; 2014 Sep; 12(9):e1001951. PubMed ID: 25226169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA Heterozygote Advantage against HIV-1 Is Driven by Quantitative and Qualitative Differences in HLA Allele-Specific Peptide Presentation.
    Arora J; Pierini F; McLaren PJ; Carrington M; Fellay J; Lenz TL
    Mol Biol Evol; 2020 Mar; 37(3):639-650. PubMed ID: 31651980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.